Redmile Group’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $235M | Sell |
632,005
-41,500
| -6% | -$12.4M | 15.77% | 2 |
|
|
2026
Q1 | $174M | Sell |
673,505
-4,200
| -0.6% | -$1.12M | 11.52% | 2 |
|
|
2025
Q4 | $167M | Buy |
677,705
+16,317
| +2% | +$3.43M | 12.3% | 2 |
|
|
2025
Q3 | $117M | Sell |
661,388
-2,083
| -0.3% | -$312K | 11.36% | 2 |
|
|
2025
Q2 | $91.2M | Sell |
663,471
-74,204
| -10% | -$10.9M | 9.71% | 2 |
|
|
2025
Q1 | $133M | Sell |
737,675
-15,500
| -2% | -$2.61M | 12.57% | 2 |
|
|
2024
Q4 | $118M | Sell |
753,175
-57,070
| -7% | -$10.1M | 8.22% | 2 |
|
|
2024
Q3 | $147M | Sell |
810,245
-210,833
| -21% | -$40.7M | 8.69% | 1 |
|
|
2024
Q2 | $188M | Sell |
1,021,078
-487,172
| -32% | -$81.8M | 11.34% | 1 |
|
|
2024
Q1 | $268M | Sell |
1,508,250
-224,939
| -13% | -$31.2M | 9.85% | 1 |
|
|
2023
Q4 | $215M | Sell |
1,733,189
-270,178
| -13% | -$30M | 7.69% | 2 |
|
|
2023
Q3 | $232M | Sell |
2,003,367
-563,294
| -22% | -$68.7M | 11.06% | 2 |
|
|
2023
Q2 | $301M | Buy |
2,566,661
+653,381
| +34% | +$66.7M | 11.57% | 2 |
|
|
2023
Q1 | $153M | Buy |
1,913,280
+16,635
| +0.9% | +$1.31M | 6.65% | 2 |
|
|
2022
Q4 | $150M | Sell |
1,896,645
-2,900
| -0.2% | -$215K | 6.15% | 2 |
|
|
2022
Q3 | $132M | Buy |
1,899,545
+1,000
| +0.1% | +$72.2K | 5.14% | 3 |
|
|
2022
Q2 | $125M | Buy |
1,898,545
+82,847
| +5% | +$5.15M | 4.76% | 5 |
|
|
2022
Q1 | $121M | Sell |
1,815,698
-5,200
| -0.3% | -$325K | 3.77% | 5 |
|
|
2021
Q4 | $127M | Sell |
1,820,898
-161,534
| -8% | -$9.4M | 2.9% | 9 |
|
|
2021
Q3 | $104M | Sell |
1,982,432
-89,700
| -4% | -$5.31M | 1.81% | 19 |
|
|
2021
Q2 | $141M | Buy |
2,072,132
+12,000
| +0.6% | +$838K | 2.09% | 14 |
|
|
2021
Q1 | $159M | Buy |
2,060,132
+385,096
| +23% | +$28M | 2.24% | 13 |
|
|
2020
Q4 | $101M | Buy |
1,675,036
+173,091
| +12% | +$8.64M | 1.22% | 23 |
|
|
2020
Q3 | $64.7M | Buy |
1,501,945
+92,200
| +7% | +$4M | 1.19% | 29 |
|
|
2020
Q2 | $58.4M | Buy |
1,409,745
+357,945
| +34% | +$17.2M | 1.08% | 29 |
|
|
2020
Q1 | $45.5M | Sell |
1,051,800
-38,400
| -4% | -$2.01M | 1.28% | 28 |
|
|
2019
Q4 | $60.4M | Buy |
1,090,200
+11,900
| +1% | +$584K | 1.44% | 23 |
|
|
2019
Q3 | $37.4M | Sell |
1,078,300
-2,000
| -0.2% | -$89.4K | 1.25% | 25 |
|
|
2019
Q2 | $43.5M | Buy |
1,080,300
+755,800
| +233% | +$24.7M | 1.23% | 26 |
|
|
2019
Q1 | $10.7M | Sell |
324,500
-500
| -0.2% | -$11.8K | 0.31% | 53 |
|
|
2018
Q4 | $6.75M | Buy |
+325,000
| New | +$6.8M | 0.27% | 57 |
|
Other funds holding KRYS
ACA
SCM
Redmile Group's KRYS Position: Q2 2026 in Review
Redmile Group reduced its Krystal Biotech (KRYS) stake by 6.2% in Q2 2026, selling an estimated $12.4M and leaving 632,005 shares worth $235M. The position accounts for 15.77% of the portfolio, ranked #2.
Redmile Group first reported a position in KRYS in Q4 2018 and has held it in 31 quarters since. The position peaked at $301M in Q2 2023. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Redmile Group held 632,005 shares of Krystal Biotech worth $235M as of Q2 2026.
- Redmile Group sold 41,500 Krystal Biotech shares in Q2 2026, an estimated $12.4M.
- Krystal Biotech made up 15.77% of Redmile Group's portfolio in Q2 2026, its #2 holding.
- Redmile Group first reported a position in Krystal Biotech in Q4 2018 and has held it in 31 quarters since.
- Redmile Group's Krystal Biotech position peaked at $301M in Q2 2023.
- 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.